

CITATION REPORT

List of articles citing

Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis

DOI: 10.1093/hmg/10.9.919

Human Molecular Genetics, 2001, 10, 919-26.

Source: <https://exaly.com/paper-pdf/33436306/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
397	Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. <i>Experimental Neurology</i> , 2001 , 172, 354-62	5.7	45
396	Induction of alpha-synuclein aggregation by intracellular nitritive insult. <i>Journal of Neuroscience</i> , 2001 , 21, 8053-61	6.6	372
395	Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. <i>Journal of Neuroscience</i> , 2001 , 21, 9549-60	6.6	496
394	6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. 2001 , 21, 771-81		47
393	Failure of the ubiquitin-proteasome system in Parkinson's disease. 2001 , 2, 589-94		416
392	Gene therapeutic approaches to the treatment of Parkinson's disease. 2001 , 1, 483-495		4
391	Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. 2002 , 82, 637-72		352
390	Parkin accumulation in aggresomes due to proteasome impairment. <i>Journal of Biological Chemistry</i> , 2002 , 277, 47870-7	5.4	114
389	Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. <i>Journal of Biological Chemistry</i> , 2002 , 277, 35050-60	5.4	94
388	Recent advances in the genetics and pathogenesis of Parkinson disease. 2002 , 58, 179-85		211
387	Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. 2002 , 16, 1826-8		169
386	Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. <i>Journal of Biological Chemistry</i> , 2002 , 277, 13935-42	5.4	96
385	Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. 2002 , 13, 1437-41		226
384	Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. 2002 , 315, 799-807		178
383	The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. 2002 , 111, 209-18		683
382	Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. 2002 , 36, 1007-19		506
381	Parkinson's disease: one biochemical pathway to fit all genes?. 2002 , 8, 236-40		59

380	Genetics of Parkinson's disease and biochemical studies of implicated gene products. 2002 , 12, 299-306		60
379	c-Jun N-terminal kinase pathway mediates Lactacystin-induced cell death in a neuronal differentiated Neuro2a cell line. 2002 , 108, 7-17		13
378	Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. 2002 , 320, 146-50		205
377	Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. 2002 , 326, 155-8		190
376	Regulation of apoptosis by the ubiquitin and proteasome pathway. 2002 , 6, 25-48		92
375	Genetics of Parkinson's disease and biochemical studies of implicated gene products. 2002 , 14, 653-60		63
374	p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. 2002 , 52, 597-606		178
373	Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. 2002 , 53, 1-10		37
372	Significance of the parkin gene and protein in understanding Parkinson's disease. 2002 , 2, 296-302		9
371	Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. <i>Journal of Neurochemistry</i> , 2002 , 81, 301-6	6	234
370	Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. <i>Journal of Neurochemistry</i> , 2002 , 83, 1030-42	6	205
369	Role and function of the 26S proteasome in proliferation and apoptosis. 2002 , 82, 965-80		212
368	Hypothesis: proteasomal dysfunction: a primary event in neurodegeneration that leads to oxidative and nitrosative stress and subsequent cell death. 2002 , 962, 182-94		90
367	Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. 2002 , 18, 229-38		84
366	Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. 2003 , 4, 21-36		333
365	Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. 2003 , 4, 95-108		47
364	Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. 2003 , 81, 678-99		1272
363	Neurodegeneration: how does parkin prevent Parkinson's disease?. 2003 , 13, R522-4		16

362	Genes and parkinsonism. 2003 , 2, 221-8		85
361	The roles of the ubiquitin-proteasome and autophagy/lysosome pathways in Huntington's disease and related conditions. 2003 , 3, 141-148		9
360	Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. 2003 , 73, 334-40		33
359	Models of Parkinson's disease. <i>Movement Disorders</i> , 2003 , 18, 729-37	7	63
358	Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. 2003 , 53 Suppl 3, S73-84; discussion S84-6		149
357	Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. <i>Journal of Neurochemistry</i> , 2003 , 85, 957-68	6	116
356	Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2003 , 86, 1297-307	6	220
355	Altered proteasomal function in sporadic Parkinson's disease. <i>Experimental Neurology</i> , 2003 , 179, 38-46	5.7	428
354	Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. 2003 , 312, 1342-8		315
353	Modulation of cell death by alpha-synuclein is stimulus-dependent in mammalian cells. 2003 , 340, 234-8		17
352	Alpha-synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone. 2003 , 351, 29-32		47
351	Neurological disease: UPS stops delivering!. 2003 , 24, 18-23		29
350	Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. 2003 , 13, 253-61		155
349	Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitin-proteasome pathway. 2003 , 26, 95-101		47
348	Parkinson's disease: mechanisms and models. 2003 , 39, 889-909		3874
347	Are Huntington's and polyglutamine-based ataxias proteasome storage diseases?. 2003 , 35, 562-71		34
346	Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. <i>Ageing Research Reviews</i> , 2003 , 2, 343-56	12	89
345	Molecular pathways of neurodegeneration in Parkinson's disease. 2003 , 302, 819-22		1382

344	Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. <i>Journal of Biological Chemistry</i> , 2003 , 278, 22044-55	5-4	221
343	Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene. 2003 , 23, 8233-45		57
342	Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. <i>Journal of Biological Chemistry</i> , 2003 , 278, 11753-9	5-4	316
341	Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. 2003 , 14, 4541-56		109
340	Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways. <i>Journal of Biological Chemistry</i> , 2003 , 278, 6371-83	5-4	85
339	Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. 2003 , 14, 565-8		61
338	Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. <i>Journal of Neuroscience</i> , 2003 , 23, 1237-45	6.6	99
337	Proteolytic dysfunction in neurodegenerative disorders. 2004 , 62, 95-119		18
336	The role of ubiquitin-protein ligases in neurodegenerative disease. 2004 , 1, 71-87		57
335	Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. <i>Journal of Neuroscience</i> , 2004 , 24, 7400-9	6.6	146
334	Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. <i>Journal of Biological Chemistry</i> , 2004 , 279, 4625-31	5-4	306
333	alpha-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines. <i>Journal of Biological Chemistry</i> , 2004 , 279, 52984-90	5-4	43
332	Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease. 2004 , 10, 63-72		14
331	alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons. <i>Journal of Biological Chemistry</i> , 2004 , 279, 46915-20	5-4	39
330	Proteasomal inhibition by alpha-synuclein filaments and oligomers. <i>Journal of Biological Chemistry</i> , 2004 , 279, 12924-34	5-4	290
329	The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. 2004 , 14, 703-11		210
328	Lewy-body formation is an aggresome-related process: a hypothesis. 2004 , 3, 496-503		235
327	Pathological proteins in Parkinson's disease: focus on the proteasome. 2004 , 24, 425-42		44

326	Proteomic approach to studying Parkinson's disease. <i>Molecular Neurobiology</i> , 2004 , 29, 271-88	6.2	28
325	Neurobiology of alpha-synuclein. <i>Molecular Neurobiology</i> , 2004 , 30, 1-21	6.2	80
324	Linkage between the proteasome pathway and neurodegenerative diseases and aging. <i>Molecular Neurobiology</i> , 2004 , 30, 201-21	6.2	33
323	Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. <i>Cell and Tissue Research</i> , 2004 , 318, 149-61	4.2	296
322	Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. 2004 , 82, 163-74		106
321	Proteome analysis of human substantia nigra in Parkinson's disease. 2004 , 4, 3943-52		217
320	Alpha-synuclein in Parkinson's disease: light from two new angles. 2004 , 55, 153-6		29
319	Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. 2004 , 56, 149-62		455
318	Roles of the proteasome in neurodegenerative disease: refining the hypothesis. 2004 , 56, 315-6		7
317	Alteration in alpha-synuclein mRNA expression in Parkinson's disease. <i>Movement Disorders</i> , 2004 , 19, 162-70	7	103
316	Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. 2004 , 36, 315-20		104
315	Genetics of neurological disorders. 2004 , 4, 317-32		13
314	Commentary on "Alpha-synuclein and mitochondria: a tangled skein". <i>Experimental Neurology</i> , 2004 , 186, 109-11	5.7	10
313	Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. 2004 , 1739, 5-25		323
312	Alpha-synuclein, Parkinson's disease, and Alzheimer's disease. 2004 , 10 Suppl 1, S9-13		42
311	Alzheimer's disease meets the ubiquitin-proteasome system. 2004 , 10, 565-70		50
310	Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. 2004 , 17, 283-9		106
309	Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. 2004 , 367, 34-9		82

308	Recent advances in research on Parkinson disease: synuclein and parkin. 2004 , 10, 75-81		24
307	Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. 2005 , 10, 235-44		27
306	Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. <i>Human Molecular Genetics</i> , 2005 , 14, 3477-92	5.6	376
305	Oxidative stress in mitochondria: decision to survival and death of neurons in neurodegenerative disorders. <i>Molecular Neurobiology</i> , 2005 , 31, 81-93	6.2	97
304	Environmental toxins and alpha-synuclein in Parkinson's disease. <i>Molecular Neurobiology</i> , 2005 , 31, 273-82		14
303	Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. <i>Journal of Neurochemistry</i> , 2005 , 93, 1304-13	6	69
302	Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity. <i>Journal of Neurochemistry</i> , 2005 , 93, 1542-50	6	24
301	Opinion: What is the role of protein aggregation in neurodegeneration?. 2005 , 6, 891-8		488
300	The role of alpha-synuclein in neurodegenerative diseases. 2005 , 105, 311-31		136
299	Apoptosis and the conformational change of Bax induced by proteasomal inhibition of PC12 cells are inhibited by bcl-xL and bcl-2. 2005 , 10, 809-20		32
298	Protein misfolding and cellular defense mechanisms in neurodegenerative diseases. 2005 , 108-130		
297	Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues. 2005 , 1, 107-20		3
296	Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation. <i>Journal of Biological Chemistry</i> , 2005 , 280, 42877-86	5.4	36
295	beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein. <i>Journal of Biological Chemistry</i> , 2005 , 280, 7562-9	5.4	44
294	Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. <i>Journal of Biological Chemistry</i> , 2005 , 280, 30649-52	5.4	152
293	Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. <i>Human Molecular Genetics</i> , 2005 , 14, 1709-25	5.6	295
292	Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. <i>Journal of Biological Chemistry</i> , 2005 , 280, 30009-17	5.4	68
291	Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. 2005 , 170, 47-59		94

290	Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. <i>Human Molecular Genetics</i> , 2005 , 14, 2063-73	5.6	348
289	Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. <i>Journal of Neuroscience</i> , 2005 , 25, 5544-52	6.6	202
288	Molecular pathophysiology of Parkinson's disease. 2005 , 28, 57-87		982
287	Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. 2005 , 16, 262-70		99
286	Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. 2005 , 351, 1081-100		201
285	Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?. 2005 , 134, 18-23		90
284	Parkinson's disease: from causes to mechanisms. 2005 , 328, 131-42		39
283	Ubiquitin-proteasome system and Parkinson's diseases. <i>Experimental Neurology</i> , 2005 , 191 Suppl 1, S17-37		159
282	The aggravating role of the ubiquitin-proteasome system in neurodegeneration. 2005 , 579, 571-6		42
281	[Animal models of parkinsonism]. 2005 , 161, 907-15		2
280	Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. 2005 , 19, 533-42		883
279	Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. <i>Human Molecular Genetics</i> , 2005 , 14, 3801-11	5.6	288
278	The biochemistry of Parkinson's disease. 2005 , 74, 29-52		536
277	Novel covalent modifications of alpha-synuclein during the recovery from proteasomal dysfunction. 2006 , 346, 1312-9		2
276	alpha-Synuclein protects SH-SY5Y cells from dopamine toxicity. 2006 , 349, 1294-300		32
275	Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. 2006 , 8, 1997-2006		165
274	Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. <i>Neurobiology of Aging</i> , 2006 , 27, 848-56	5.6	81
273	Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. <i>Neurobiology of Aging</i> , 2006 , 27, 530-45	5.6	122

272	Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. 2006 , 24, 3153-62	126
271	Convergent pathobiologic model of Parkinson's disease. 2003 , 991, 152-66	39
270	Modifications of the iron-neuromelanin system in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2006 , 96, 909-16	6 97
269	Embryonic stem cell-derived neuron models of Parkinson's disease exhibit delayed neuronal death. <i>Journal of Neurochemistry</i> , 2006 , 98, 45-56	6 19
268	Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in <i>Caenorhabditis elegans</i> . <i>Journal of Neurochemistry</i> , 2006 , 98, 576-87	6 48
267	Parkinsonism genes: culprits and clues. <i>Journal of Neurochemistry</i> , 2006 , 99, 1062-72	6 92
266	alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease. 2006 , 6, 1107-16	39
265	Expanding insights of mitochondrial dysfunction in Parkinson's disease. 2006 , 7, 207-19	686
264	Ageing and neuronal vulnerability. 2006 , 7, 278-94	728
263	Metastable, partially folded states in the productive folding and in the misfolding and amyloid aggregation of proteins. 2006 , 44, 539-48	21
262	Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. 2006 , 1, 151-70	293
261	Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. 2006 , 11, 955-66	69
260	Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. 2006 , 112, 115-26	68
259	Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. 2006 , 7, 139-48	73
258	Identification of gene expression changes in transgenic <i>C. elegans</i> overexpressing human alpha-synuclein. 2006 , 22, 477-86	66
257	Proteasome dysfunction in aged human alpha-synuclein transgenic mice. 2006 , 23, 120-6	69
256	Ubiquitin-proteasome system and Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1806-23	7 153
255	The role of chaperones in Parkinson's disease and prion diseases. 2006 , 221-58	13

254	Alpha-synuclein overexpression increases cytosolic catecholamine concentration. <i>Journal of Neuroscience</i> , 2006 , 26, 9304-11	6.6	125
253	Lewy bodies. 2006 , 103, 1661-8		329
252	Proteasomal dysfunction: a common feature of neurodegenerative diseases? Implications for the environmental origins of neurodegeneration. 2006 , 8, 2007-19		32
251	Parkinson's disease: genetics and beyond. <i>Current Neuropharmacology</i> , 2007 , 5, 99-113	7.6	20
250	alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity. <i>Journal of Biological Chemistry</i> , 2007 , 282, 5736-48	5.4	28
249	Parkinson Disease: Molecular Insights. 2007 , 221-239		
248	Impairment of the ubiquitin-proteasome pathway is a downstream endoplasmic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic beta-cell apoptosis. 2007 , 56, 2284-94		105
247	YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation. 2007 , 177, 1091-104		54
246	Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H ₂ O ₂ - and Sin-1-induced cell death. <i>Neurobiology of Aging</i> , 2007 , 28, 1709-17	5.6	47
245	Activation of the unfolded protein response in Parkinson's disease. 2007 , 354, 707-11		367
244	Gene-environment interactions in Parkinson's disease. 2007 , 13 Suppl 3, S309-15		59
243	Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies. <i>Expert Review of Proteomics</i> , 2007 , 4, 769-81	4.2	61
242	Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. 2007 , 9, 553-61		91
241	Parkinson's disease: animal models. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 83, 265-87	3	9
240	Genetic aspects of Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 83, 217-44	3	2
239	Protein-handling dysfunction in Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 83, 571-90	3	
238	Are heat shock proteins therapeutic target for Parkinson's disease?. 2006 , 3, 20-6		39
237	Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. 2007 , 55, 1178-88		126

236	Role of the ubiquitin proteasome system in Parkinson's disease. 2007 , 8 Suppl 1, S13		80
235	The proteomic approach in Parkinson's disease. 2007 , 1, 1428-35		7
234	Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity. 2007 , 43, 65-73		43
233	Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. 2007 , 1153, 196-203		21
232	Polyglutamine-expanded ataxin-7 decreases nuclear translocation of NF-kappaB p65 and impairs NF-kappaB activity by inhibiting proteasome activity of cerebellar neurons. 2007 , 19, 573-81		16
231	Neuroprotection against neurodegenerative diseases. <i>Molecular Neurobiology</i> , 2007 , 35, 55-84	6.2	23
230	Calcium elevation in mouse pancreatic beta cells evoked by extracellular human islet amyloid polypeptide involves activation of the mechanosensitive ion channel TRPV4. 2008 , 51, 2252-62		97
229	Genes associated with Parkinson syndrome. 2008 , 255 Suppl 5, 8-17		69
228	Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice. 2008 , 8, 1266-75		33
227	Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?. 2008 , 7, 129-51		69
226	Controlling the mass action of alpha-synuclein in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2008 , 107, 303-16	6	75
225	Review: Familial Parkinson's disease--genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. 2008 , 34, 255-71		88
224	Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. 2008 , 314, 2076-89		153
223	Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data. 2008 , 45, 1290-301		15
222	Mitochondrial DNA damage and repair in neurodegenerative disorders. 2008 , 7, 1110-20		122
221	Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. 2008 , 12, 2263-80		191
220	Immunological features of alpha-synuclein in Parkinson's disease. 2008 , 12, 1820-9		75
219	Molecular and cellular biology of synucleins. 2008 , 270, 225-317		73

218	Differential effects of overexpression of wild-type and mutant human alpha-synuclein on MPP+-induced neurotoxicity in PC12 cells. 2008 , 435, 142-6		31
217	Mitochondria in neuroplasticity and neurological disorders. 2008 , 60, 748-66		688
216	Alpha-synuclein and Parkinson's disease: a proteomic view. <i>Expert Review of Proteomics</i> , 2008 , 5, 239-48	4.2	26
215	Cell systems and the toxic mechanism(s) of alpha-synuclein. <i>Experimental Neurology</i> , 2008 , 209, 5-11	5.7	141
214	Is malfunction of the ubiquitin proteasome system the primary cause of alpha-synucleinopathies and other chronic human neurodegenerative disease?. 2008 , 1782, 683-90		24
213	The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. 2008 , 27, 336-49		279
212	Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. <i>Journal of Biological Chemistry</i> , 2008 , 283, 23179-88	5.4	101
211	alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. <i>Journal of Biological Chemistry</i> , 2008 , 283, 20288-98	5.4	88
210	Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. <i>Journal of Biological Chemistry</i> , 2008 , 283, 10992-1003	5.4	182
209	Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2008 , 67, 402-16	3.1	157
208	Neuroprotective and Neurotoxic Properties of α Synuclein in Cell Culture Models of Dopaminergic Degeneration. 2008 , 475-490		
207	PC12 Cells as a model for parkinson's disease research. 2008 , 375-387		14
206	Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. <i>Journal of Clinical Investigation</i> , 2008 , 118, 777-88	15.9	461
205	S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. 2009 , 106, 4900-5		123
204	Synphilin-1A inhibits seven in absentia homolog (SIAH) and modulates alpha-synuclein monoubiquitylation and inclusion formation. <i>Journal of Biological Chemistry</i> , 2009 , 284, 11706-16	5.4	24
203	Modeling proteasome dynamics in Parkinson's disease. 2009 , 6, 036005		16
202	Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. 2009 , 35, 385-98		320
201	Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. 2009 , 14, 478-500		216

200	alpha-Synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress. 2009 , 39, 226-34	41
199	Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. 2009 , 4, 24	84
198	alpha-Synuclein and neuronal cell death. 2009 , 4, 9	257
197	The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?. 2009 , 61, 1316-23	38
196	Intrabody and Parkinson's disease. 2009 , 1792, 634-42	19
195	Molecular mechanisms of alpha-synuclein neurodegeneration. 2009 , 1792, 616-24	156
194	Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. 2009 , 1792, 651-63	178
193	A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. 2009 , 1792, 664-75	76
192	Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. 2009 , 64, 807-27	392
191	The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. 2009 , 389, 413-24	103
190	Manganese-induced dopaminergic neurodegeneration: insights into mechanisms and genetics shared with Parkinson's disease. 2009 , 109, 4862-84	98
189	Protein misfolding and aggregation in Parkinson's disease. 2009 , 11, 2119-34	71
188	Endoplasmic Reticulum Stress in Neurodegeneration. <i>Focus on Structural Biology</i> , 2009 , 111-132	3
187	Parkinson-linked genes and toxins that affect neuronal cell death through the Bcl-2 family. 2009 , 11, 529-40	31
186	Endoplasmic reticulum stress in disease: mechanisms and therapeutic opportunities. 2009 , 118, 19-29	122
185	Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue. 2010 , 17, 215-27	16
184	B-Crystallin inhibits the cell toxicity associated with amyloid fibril formation by Ictasein and the amyloid-beta peptide. 2010 , 15, 1013-26	51
183	The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease. 2010 , 64, 241-50	30

182	Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familial Parkinsonism. <i>Journal of Neurochemistry</i> , 2010 , 114, 419-29	6	63
181	The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases. 2010 , 1, 15		10
180	Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. <i>Frontiers in Aging Neuroscience</i> , 2010 , 2, 17	5.3	29
179	Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. 2010 , 4, 140		49
178	Mutations in NOTCH3 cause the formation and retention of aggregates in the endoplasmic reticulum, leading to impaired cell proliferation. <i>Human Molecular Genetics</i> , 2010 , 19, 79-89	5.6	44
177	Increased E4 activity in mice leads to ubiquitin-containing aggregates and degeneration of hypothalamic neurons resulting in obesity. <i>Journal of Biological Chemistry</i> , 2010 , 285, 15538-15547	5.4	13
176	Parkin directly modulates 26S proteasome activity. <i>Journal of Neuroscience</i> , 2010 , 30, 11805-14	6.6	67
175	Extracellular dopamine potentiates mn-induced oxidative stress, lifespan reduction, and dopaminergic neurodegeneration in a BLI-3-dependent manner in <i>Caenorhabditis elegans</i> . 2010 , 6, e1001084		141
174	The impact of genetic research on our understanding of Parkinson's disease. <i>Progress in Brain Research</i> , 2010 , 183, 21-41	2.9	26
173	Protein quality control mechanisms and neurodegenerative disorders: Checks, balances and deadlocks. 2010 , 68, 159-66		21
172	Mitochondrial dysfunction in Parkinson's disease. 2010 , 1802, 29-44		383
171	New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease. 2010 , 1802, 935-41		48
170	Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. <i>Neurobiology of Aging</i> , 2010 , 31, 953-68	5.6	160
169	Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. 2011 , 63, 439-44		104
168	Protective role of heat shock proteins in Parkinson's disease. 2011 , 8, 155-68		52
167	Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression. <i>Neurochemistry International</i> , 2011 , 59, 280-9	4.4	20
166	DNA repair deficiency in neurodegeneration. <i>Progress in Neurobiology</i> , 2011 , 94, 166-200	10.9	235
165	The Role of Neuroinflammation in Parkinson's Disease. 2011 , 403-421		4

164	Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. 2010 , 2011, 617472		41
163	What genetics tells us about the causes and mechanisms of Parkinson's disease. 2011 , 91, 1161-218		422
162	Parkinson's disease, proteins, and prions: milestones. <i>Movement Disorders</i> , 2011 , 26, 1056-71	7	33
161	Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. <i>Movement Disorders</i> , 2011 , 26, 2316-23	7	46
160	Genetic mouse models of neurodegenerative diseases. 2011 , 100, 419-82		33
159	Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of β synuclein. <i>Journal of Neuroscience</i> , 2011 , 31, 14508-20	6.6	268
158	Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. <i>Journal of Biological Chemistry</i> , 2011 , 286, 20710-26	5.4	423
157	The mitochondrial chaperone protein TRAP1 mitigates β synuclein toxicity. 2012 , 8, e1002488		105
156	β synuclein, LRRK2 and their interplay in Parkinson's disease. 2012 , 7, 145-153		30
155	Programmed cell death in Parkinson's disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012 , 2,	5.4	148
154	Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness?. <i>Experimental Neurology</i> , 2012 , 238, 89-99	5.7	33
153	Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse. 2012 , 53, 1791-806		75
152	Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2012 , 122, 404-14	6	106
151	Molecular insights into Parkinson's disease. 2012 , 107, 125-88		59
150	Mitochondrial dysfunction in genetic animal models of Parkinson's disease. 2012 , 16, 896-919		67
149	Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice. 2012 , 44, 76-85		20
148	β synuclein in Parkinson's disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012 , 2, a009399	5.4	625
147	Aspects of innate immunity and Parkinson's disease. 2012 , 3, 33		13

146	Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. 2012 , 2012, 391438		25
145	E3 ubiquitin ligases in protein quality control mechanism. <i>Molecular Neurobiology</i> , 2012 , 45, 571-85	6.2	21
144	Protein degradation pathways in Parkinson's disease: curse or blessing. 2012 , 124, 153-72		175
143	Conditional expression of Parkinson's disease-related mutant β synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. <i>Journal of Neuroscience</i> , 2012 , 32, 9248-64	6.6	134
142	The role of β synuclein in neurodegeneration □An update. 2012 , 3,		12
141	Proteinopathies, neurodegenerative disorders with protein aggregation-based pathology. 2012 , 46, 362-374		36
140	Mitochondrial dysfunction precedes other sub-cellular abnormalities in an in vitro model linked with cell death in Parkinson's disease. 2012 , 21, 185-94		22
139	Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. 2013 , 62, 186-201		60
138	Exceptionally high cumulative percentage of NUMTs originating from linear mitochondrial DNA molecules in the Hydra magnipapillata genome. 2013 , 14, 447		15
137	β synuclein and neuronal cell death. <i>Molecular Neurobiology</i> , 2013 , 47, 466-83	6.2	82
136	Microglial activation and antioxidant responses induced by the Parkinson's disease protein β synuclein. 2013 , 8, 94-117		121
135	β synuclein and protein degradation systems: a reciprocal relationship. <i>Molecular Neurobiology</i> , 2013 , 47, 537-51	6.2	179
134	Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in β synuclein transgenic mice. 2013 , 14, 135		5
133	Alpha-synuclein and protein degradation pathways in Parkinson's disease: a pathological feed-back loop. <i>Experimental Neurology</i> , 2013 , 247, 308-13	5.7	30
132	Mitochondrial dysfunction and oxidative stress in Parkinson's disease. <i>Progress in Neurobiology</i> , 2013 , 106-107, 17-32	10.9	369
131	Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. <i>Movement Disorders</i> , 2013 , 28, 31-40	7	249
130	Gingerol-induced hypoxia-inducible factor 1 alpha inhibits human prion peptide-mediated neurotoxicity. 2013 , 27, 1185-92		8
129	Xenobiotic perturbation of ER stress and the unfolded protein response. 2013 , 41, 235-62		19

128	Copper and copper proteins in Parkinson's disease. 2014 , 2014, 147251		97
127	The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. <i>Frontiers in Molecular Neuroscience</i> , 2014 , 7, 70	6.1	190
126	Failure of ubiquitin proteasome system: risk for neurodegenerative diseases. 2014 , 14, 161-75		23
125	Neurodegenerative disorders: dysregulation of a carefully maintained balance?. 2014 , 58, 279-91		14
124	RTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway. <i>Journal of Neuroscience</i> , 2014 , 34, 16076-85	6.6	30
123	Targeting β Synuclein as a Parkinson's Disease Therapeutic. 2014 , 43-109		
122	The ubiquitin proteasome system in glia and its role in neurodegenerative diseases. <i>Frontiers in Molecular Neuroscience</i> , 2014 , 7, 73	6.1	72
121	Neuronal Death Mechanisms in Development and Disease. 2014 , 167-188		1
120	β Synuclein in Parkinson's disease: pathogenic function and translation into animal models. 2014 , 14, 1-17		34
119	Integrating pathways of Parkinson's disease in a molecular interaction map. <i>Molecular Neurobiology</i> , 2014 , 49, 88-102	6.2	178
118	Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular β Synuclein in oligodendrocytes. 2014 , 52, 339-52		33
117	Ageing and Parkinson's disease: why is advancing age the biggest risk factor?. <i>Ageing Research Reviews</i> , 2014 , 14, 19-30	12	487
116	Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease. 2014 , 21, 471-84		33
115	β Synuclein is localized to mitochondria-associated ER membranes. <i>Journal of Neuroscience</i> , 2014 , 34, 249-59	6.6	332
114	Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. 2014 , 62, 68-78		33
113	β Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2014 , 131, 868-77	6	41
112	Biophysical groundwork as a hinge to unravel the biology of β Synuclein aggregation and toxicity. 2014 , 47, 1-48		30
111	Protein phosphorylation in neurodegeneration: friend or foe?. <i>Frontiers in Molecular Neuroscience</i> , 2014 , 7, 42	6.1	146

110	Alpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease. <i>Biomolecules</i> , 2015 , 5, 2675-700	5.9	33
109	Sirtuins and proteolytic systems: implications for pathogenesis of synucleinopathies. <i>Biomolecules</i> , 2015 , 5, 735-57	5.9	7
108	Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role. <i>Biomolecules</i> , 2015 , 5, 865-92	5.9	29
107	Use of <i>Caenorhabditis elegans</i> to Model Human Movement Disorders. 2015 , 97-116		
106	Effect of amyloids on the vesicular machinery: implications for somatic neurotransmission. 2015 , 370,		11
105	Genetic Models of Parkinson's Disease: Behavior, Signaling, and Pathological Features. 2015 , 289-314		
104	Parkinson disease mutant E46K enhances Synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo. <i>Journal of Biological Chemistry</i> , 2015 , 290, 9412-27	5.4	41
103	Intracellular Dynamics of Synucleins: "Here, There and Everywhere". 2015 , 320, 103-69		47
102	Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. 2015 , 81, 76-92		47
101	Parkinson's Disease: The Mitochondria-Iron Link. 2016 , 2016, 7049108		36
100	Aggregated Alpha-Synuclein Transfer Efficiently between Cultured Human Neuron-Like Cells and Localize to Lysosomes. <i>PLoS ONE</i> , 2016 , 11, e0168700	3.7	38
99	Comparison of Optical Coherence Tomography Findings in Patients With Primary Open-angle Glaucoma and Parkinson Disease. 2016 , 25, e639-46		15
98	Protein Partners of Synuclein in Health and Disease. 2016 , 26, 389-97		28
97	BPOZ-2 Gene Delivery Ameliorates Alpha-Synucleinopathy in A53T Transgenic Mouse Model of Parkinson's Disease. <i>Scientific Reports</i> , 2016 , 6, 22067	4.9	6
96	Silica nanoparticles induce alpha-synuclein induction and aggregation in PC12-cells. <i>Chemico-Biological Interactions</i> , 2016 , 258, 197-204	5	49
95	Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. <i>Journal of Neurochemistry</i> , 2016 , 139 Suppl 1, 240-255	6	95
94	Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. <i>Journal of Neurochemistry</i> , 2016 , 136, 222-33	6	38
93	Parkinson's Disease-Associated Mutations Affect Mitochondrial Function. 2016 , 139-158		1

92	Glycation in Parkinson's disease and Alzheimer's disease. <i>Movement Disorders</i> , 2016 , 31, 782-90	7	74
91	The Proteasome Inhibition Model of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017 , 7, 31-63	5.3	55
90	Ferroptosis and cell death mechanisms in Parkinson's disease. <i>Neurochemistry International</i> , 2017 , 104, 34-48	4.4	165
89	Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017 , 37, 1910-1926	7.3	35
88	Proteomic studies associated with Parkinson's disease. <i>Expert Review of Proteomics</i> , 2017 , 14, 193-209	4.2	8
87	Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) Aggregation Causes Mitochondrial Dysfunction during Oxidative Stress-induced Cell Death. <i>Journal of Biological Chemistry</i> , 2017 , 292, 4727-4742	5.4	36
86	Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease. <i>Experimental Neurology</i> , 2017 , 298, 162-171	5.7	31
85	α-Synuclein Oligomers: A Study in Diversity. <i>Israel Journal of Chemistry</i> , 2017 , 57, 699-723	3.4	12
84	The Parkinson's disease-associated protein DJ-1 plays a positive nonmitochondrial role in endocytosis in cells. <i>DMM Disease Models and Mechanisms</i> , 2017 , 10, 1261-1271	4.1	15
83	Sigma-1 receptor knockout increases α-Synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra. <i>Neurobiology of Aging</i> , 2017 , 59, 171-183	5.6	23
82	Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia. <i>Ageing Research Reviews</i> , 2017 , 34, 30-38	12	46
81	Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications. <i>Biological Chemistry</i> , 2017 , 398, 77-100	4.5	37
80	Trehalose Inhibits A53T Mutant α-Synuclein Overexpression and Neurotoxicity in Transduced PC12 Cells. <i>Molecules</i> , 2017 , 22,	4.8	11
79	RNA Interference of Human α-Synuclein in Mouse. <i>Frontiers in Neurology</i> , 2017 , 8, 13	4.1	13
78	The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology. <i>Frontiers in Molecular Neuroscience</i> , 2017 , 10, 311	6.1	13
77	Proteasome impairment by α-Synuclein. <i>PLoS ONE</i> , 2017 , 12, e0184040	3.7	32
76	Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 797-810	4.4	147
75	The concept of alpha-synuclein as a prion-like protein: ten years after. <i>Cell and Tissue Research</i> , 2018 , 373, 161-173	4.2	85

74	Inducible Alpha-Synuclein Expression Affects Human Neural Stem Cells' Behavior. <i>Stem Cells and Development</i> , 2018 , 27, 985-994	4.4	2
73	A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. <i>Nature Communications</i> , 2018 , 9, 1097	17.4	135
72	Cell Biology and Pathophysiology of β Synuclein. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018 , 8,	5.4	176
71	Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018 , 12, 413	6.1	8
70	Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity. <i>Animal Cells and Systems</i> , 2018 , 22, 273-280	2.3	5
69	Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	110
68	Parkinson's disease: Network analysis of publications' impact. 2018 ,		
67	Neurochemical Aspects of Traumatic Brain Injury. 2018 , 239-286		
66	Bone Marrow Mesenchymal Stem Cells' Secretome Exerts Neuroprotective Effects in a Parkinson's Disease Rat Model. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019 , 7, 294	5.8	35
65	Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease. <i>Stem Cell Reports</i> , 2019 , 12, 213-229	8	154
64	The Impairments of β Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019 , 13, 1028	5.1	37
63	β Synuclein in Parkinson's disease: causal or bystander?. <i>Journal of Neural Transmission</i> , 2019 , 126, 815-840.	4.3	53
62	Nonenzymatic Posttranslational Protein Modifications: Mechanism and Associated Disease Pathologies. 2019 , 229-280		1
61	Regulation of Autophagy by Nuclear GAPDH and Its Aggregates in Cancer and Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	36
60	Dysfunction of Cellular Proteostasis in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019 , 13, 457	5.1	54
59	Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation. <i>Phytomedicine</i> , 2019 , 61, 152842	6.5	16
58	New insights into the complex role of mitochondria in Parkinson's disease. <i>Progress in Neurobiology</i> , 2019 , 177, 73-93	10.9	138
57	Calcium Channel α_1 Subunit Mediates Secondary Orofacial Hyperalgesia Through PKC-TRPA1/Gap Junction Signaling. <i>Journal of Pain</i> , 2020 , 21, 238-257	5.2	10

56	From Synaptic Protein to Prion: The Long and Controversial Journey of β Synuclein. <i>Frontiers in Synaptic Neuroscience</i> , 2020 , 12, 584536	3.5	12
55	Proteotoxicity and Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	13
54	In Search of Effective Treatments Targeting β Synuclein Toxicity in Synucleinopathies: Pros and Cons. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 559791	5.7	9
53	SUMOylation in β Synuclein Homeostasis and Pathology. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 167	5.3	7
52	Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by β Synuclein. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 17	7.3	27
51	Dysregulated Interorganellar Crosstalk of Mitochondria in the Pathogenesis of Parkinson's Disease. <i>Cells</i> , 2020 , 9,	7.9	26
50	Protein Quality Control Pathways at the Crossroad of Synucleinopathies. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 369-382	5.3	12
49	Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases. <i>Frontiers in Physiology</i> , 2020 , 11, 361	4.6	10
48	Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: Virus-based models versus inoculation of exogenous preformed toxic species. <i>Journal of Neuroscience Methods</i> , 2020 , 338, 108685	3	8
47	Pathways of protein synthesis and degradation in PD pathogenesis. <i>Progress in Brain Research</i> , 2020 , 252, 217-270	2.9	3
46	Physiology of cellular demise: Apoptosis, necrosis, and autophagy. 2021 , 23-78		
45	Expanding the role of proteasome homeostasis in Parkinson's disease: beyond protein breakdown. <i>Cell Death and Disease</i> , 2021 , 12, 154	9.8	5
44	β Synuclein Up-regulates Monoamine Oxidase A Expression and Activity Trans-Acting Transcription Factor 1. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 653379	5.3	3
43	Neurons and Glia Interplay in β Synucleinopathies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
42	Impact of Fatty Acid-Binding Proteins in β Synuclein-Induced Mitochondrial Injury in Synucleinopathy. <i>Biomedicines</i> , 2021 , 9,	4.8	4
41	β Synuclein Decreases the Abundance of Proteasome Subunits and Alters Ubiquitin Conjugates in Yeast. <i>Cells</i> , 2021 , 10,	7.9	1
40	The Ubiquitin-Proteasome System in Parkinson's Disease. 169-194		1
39	Protein Aggregation and the UPS: A Two-Way Street. 2006 , 39-55		1

38	Inhibition of α -Synuclein Aggregation by Antioxidants and Chaperones in Parkinson's Disease. <i>Focus on Structural Biology</i> , 2009 , 175-206		4
37	Alpha Synuclein in Parkinson's Disease. 2014 , 691-726		1
36	MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease. 2014 , 237-275		2
35	We Are What We Eat: Ubiquitin-Proteasome System (UPS) Modulation Through Dietary Products. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1233, 329-348	3.6	1
34	Progress in familial Parkinson's disease. <i>Journal of Neural Transmission Supplementum</i> , 2006 , 191-204		14
33	Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of α -Synuclein. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008 , PAP, 402-16	3.1	107
32	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. <i>Journal of Clinical Investigation</i> , 2003 , 111, 145-51	15.9	61
31	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. <i>Journal of Clinical Investigation</i> , 2003 , 111, 145-151	15.9	152
30	Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4544-54	15.9	38
29	Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. <i>Journal of Neuroscience</i> , 2002 , 22, 10690-8	6.6	457
28	Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. <i>Current Neuropharmacology</i> , 2013 , 11, 338-78	7.6	313
27	Drug targets from genetics: α -Synuclein. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011 , 10, 712-23	2.6	8
26	Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications. <i>Nano Research</i> , 1	10	1
25	Ubiquitin and Intracellular Aggregation. 2003 , 185-193		
24	Use of <i>C. elegans</i> to Model Human Movement Disorders. 2005 , 111-126		1
23	Etiology and pathogenesis of Parkinson's disease. <i>Juntendo Igaku</i> , 2006 , 52, 152-162	1	
22	The Proteasome, Protein Aggregation, and Neurodegeneration. 2007 , 371-408		
21	Involvement of Caspases in the Pathophysiology of Neurodegeneration and Stroke. 2014 , 47-66		0

20 Proteases in Neuropathophysiology. **2017**, 131-145

19 Inducible alpha-synuclein overexpression affects human Neural Stem Cells behavior.

18 Parkinson Disease and Related Disorders. **2006**, 199-212

17 The Proteasome: Source and a Target of Oxidative Stress?. **2006**, 85-103

16 Cell Biology of Synuclein: Implications in Parkinson Disease and Other Lewy Body Diseases. 111-124

15 Neurogenetics in Parkinson's Disease. **2008**, 9-16

14 Advances in Proteasome Enhancement by Small Molecules.. *Biomolecules*, **2021**, 11, 5.9 1

13 Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders. *International Journal of Molecular Sciences*, **2021**, 22, 6.3 2

12 Alpha-synuclein and cortico-striatal plasticity in animal models of Parkinson disease.. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2022**, 184, 153-166 3 1

11 Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin. *Molecular Neurobiology*, **2007**, 35, 55-84 6.2 8

10 Neuroglial Senescence, Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson's Disease.. *Frontiers in Neuroscience*, **2022**, 16, 824191 5.1 1

9 CHAPTER 10. Protein Oxidation, Quality-Control Mechanisms and Parkinson Disease. *Issues in Toxicology*, 277-324 0.3

8 Table_1.XLSX. **2019**,

7 Presentation_1.PPT. **2019**,

6 Table_1.DOC. **2019**,

5 Exploring the role of protein quality control in aging and age-associated neurodegenerative diseases. **2022**, 139-171 0

4 Synuclein Proteins in MPTP-Induced Death of Substantia Nigra Pars Compacta Dopaminergic Neurons. **2022**, 10, 2278 0

3 Role of fatty acid-binding protein 7 and novel therapeutic approach in synucleinopathies. **2022**, 157, 396-400 0

- 2 SIAH proteins regulate the degradation and intra-mitochondrial aggregation of PINK1 : Implications for mitochondrial pathology in Parkinson's disease. ○
- 1 Kisspeptin-10 Mitigates β -Synuclein-Mediated Mitochondrial Apoptosis in SH-SY5Y-Derived Neurons via a Kisspeptin Receptor-Independent Manner. **2023**, 24, 6056 ○